Docking and quantitative structure–activity relationship studies for imidazo[1,2-a]pyrazines as inhibitors of checkpoint kinase-1

Overview of attention for article published in Medicinal Chemistry Research, July 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#4 of 452)
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

patent: 9 patents

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 8 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 9 patents that reference this research output.

Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof

Grant US-11040978-B2

United States of America

Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof

Grant US-10280168-B2

United States of America

Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof

Grant US-9908886-B2

United States of America

IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

Application EA-028041-B1

Eurasian Patent Organisation

Substituted imidazo[1,2-a]pyrazines as TNF activity modulators

Grant US-9475820-B2

United States of America

Imidazopyrazine derivatives as modulators of tnf activity

Application CN-104470924-A

China

Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof

Application CN-104350055-A

China

IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

Application WO-2014009296-A1

World Intellectual Property Organisation (WIPO)

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

Application WO-2013147711-A1

World Intellectual Property Organisation (WIPO)